Fig. 4: Genetic or pharmacologic inhibition of DNL increases PUFA fatty acid composition in liver and positively affects DHA-supplementation therapy outcome.
From: Fatty acid synthesis suppresses dietary polyunsaturated fatty acid use
a TAG fatty acid class composition of livers and (b) plasma TAG levels of 2 weeks HFD fed female Chrepb−/− mice (Chrepb−/− HFD, n = 5) or female wild type littermates (Control HFD, n = 5) without or with DHA supplementation for another week (Control HFD + DHA, n = 5; Chrepb−/− HFD + DHA, n = 6) (data are shown as mean ± SEM; two-way ANOVA and Fisher’s LSD test, with (*) indicates significant differences versus respective non-DHA-supplemented group. a SAFA: Chrepb−/− HFD + DHA *P = 0.0093; MUFA: Control HFD + DHA *P = 0.0241, Chrepb−/− HFD + DHA *P = 0.0031; PUFA: Chrepb−/− HFD + DHA *P = 0.0007. b Chrepb−/− HFD + DHA *P = 0.0306). c Liver fatty acid class profile and (d) liver TAG of male wild type mice fed a high-fat diet for two weeks and an additional week without or with DHA supplementation and receiving one week of daily TVB-2640 or control gavage (data are shown as mean ± SEM; n = 5 HFD, n = 6 HFD + TVB-3664, n = 6 HFD + DHA, n = 6 HFD + DHA + TVB-3664; significant differences were assessed using two-way ANOVA and Fisher’s LSD test with (*) indicating significant differences vs. HFD, ($) showing significant differences vs. HFD + TVB-3664, and (#) showing significant differences vs. HFD + DHA. c MUFA: *P = 0.0024; $ P = 0.0015; # P = 0.0141; PUFA: *P = 0.0459; $ P = 0.0087. d *P = 0.0159 $ P = 0.0293; # P = 0.0053). Source data are provided as a Source Data file.
